Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-12-2023 | Bevacizumab | Case report

Bevacizumab/dorzolamide/nepafenac

Lack of efficacy: case report

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Elhusseiny AM, et al. Regression of treatment-resistant gyrate atrophy-associated intraretinal cystic spaces using long-term diet restriction: A case report. European Journal of Ophthalmology 33: NP1-NP4, No. 3, May 2023. Available from: URL: https://journals.sagepub.com/home/EJO Elhusseiny AM, et al. Regression of treatment-resistant gyrate atrophy-associated intraretinal cystic spaces using long-term diet restriction: A case report. European Journal of Ophthalmology 33: NP1-NP4, No. 3, May 2023. Available from: URL: https://​journals.​sagepub.​com/​home/​EJO
Metadata
Title
Bevacizumab/dorzolamide/nepafenac
Lack of efficacy: case report
Publication date
01-12-2023
Publisher
Springer International Publishing
Keyword
Bevacizumab
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51410-6

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Clozapine

Case report

Prednisolone

Case report

Dexmedetomidine

Case report

Multiple drugs

Case report

Alemtuzumab